As of 2025-07-06, the EV/EBITDA ratio of Unicycive Therapeutics Inc (UNCY) is -2.59. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. UNCY's latest enterprise value is 62.20 mil USD. UNCY's TTM EBITDA according to its financial statements is -24.01 mil USD. Dividing these 2 quantities gives us the above UNCY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-04-16 | 0.38 |
| 2025-04-15 | 0.38 |
| 2025-04-14 | 0.37 |
| 2025-04-11 | 0.42 |
| 2025-04-10 | 0.43 |
| 2025-04-09 | 0.44 |
| 2025-04-08 | 0.47 |
| 2025-04-07 | 0.48 |
| 2025-04-04 | 0.44 |
| 2025-04-03 | 0.39 |
| 2025-04-02 | 0.42 |
| 2025-04-01 | 0.42 |
| 2025-03-31 | 0.40 |
| 2025-03-28 | 0.37 |
| 2025-03-27 | 0.36 |
| 2025-03-26 | 0.36 |
| 2025-03-25 | 0.35 |
| 2025-03-24 | 0.35 |
| 2025-03-21 | 0.32 |
| 2025-03-20 | 0.34 |
| 2025-03-19 | 0.33 |
| 2025-03-18 | 0.38 |
| 2025-03-17 | 0.39 |
| 2025-03-14 | 0.39 |
| 2025-03-13 | 0.39 |
| 2025-03-12 | 0.39 |
| 2025-03-11 | 0.39 |
| 2025-03-10 | 0.42 |
| 2025-03-07 | 0.40 |
| 2025-03-06 | 0.41 |
| 2025-03-05 | 0.41 |
| 2025-03-04 | 0.44 |
| 2025-03-03 | 0.44 |
| 2025-02-28 | 0.42 |
| 2025-02-27 | 0.40 |
| 2025-02-26 | 0.40 |
| 2025-02-25 | 0.42 |
| 2025-02-24 | 0.40 |
| 2025-02-21 | 0.37 |
| 2025-02-20 | 0.37 |
| 2025-02-19 | 0.38 |
| 2025-02-18 | 0.36 |
| 2025-02-14 | 0.38 |
| 2025-02-13 | 0.41 |
| 2025-02-12 | 0.43 |
| 2025-02-11 | 0.43 |
| 2025-02-10 | 0.42 |
| 2025-02-07 | 0.40 |
| 2025-02-06 | 0.37 |
| 2025-02-05 | 0.36 |